Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance
Filings
33 filings of NEULANDLAB since February 2025.
board outcome 9, presentation 8, transcript 8, credit rating 4, results 2, dividend 2
| Filed | Type | Subject | |
|---|---|---|---|
| 06 Nov 2026 | transcript Acquisition, Capex, Guidance, Results | Transcript of the Earnings Call conducted on November 3, 2026AI summaryNeuland Laboratories filed the transcript of its Q2 and H1 FY27 earnings conference call held on November 3, 2026, for the quarter and half year ended September 30, 2026. Total income for Q2 FY27 was Rs.457.2 crores versus Rs.516.1 crores a year earlier; H1 FY27 total income was Rs.1,107.2 crores versus Rs.816.7 crores in H1 FY26. Gross margin for the quarter was 59.4% (60.1% in Q2 FY26); EBITDA was Rs.104.6 crores at a 22.9% margin (Rs.156.9 crores, 30.4% margin); profit after tax was Rs.51.1 crores (Rs.96.5 crores). Management said the quarter's revenue moderation reflected lumpiness in commercial shipment timing, and that the first half was largely in line with expectations; growth expectations for H2 FY27 and FY28 remain intact. Management said H1 FY27 capex was Rs.261 crores, free cash flow Rs.99 crores, net debt negative Rs.208 crores, and working capital 104 days of sales; the Board approved additional land for the Unit I footprint and about 134 acres were acquired at Kakinada. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | presentation Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q2FY27 and H1FY27 results for the quarter and half year ended September 30, 2026. Standalone total income for Q2FY27 was Rs. 457.2 crore, down 11.4% YoY; EBITDA was Rs. 104.6 crore (EBITDA margin 22.9%, down 754 bps YoY); PAT was Rs. 51.1 crore, down 47.0% YoY (PAT margin 11.2%). Diluted EPS for Q2FY27 was Rs. 39.9 versus Rs. 75.2 in Q2FY26; net debt stood at Rs. (208.0) crore at Q2FY27 end. Working capital days reduced to 104 days in H1FY27 from 155 days in H1FY26; capex cash outflow was Rs. 261 crore, driven by new R&D and the peptide block. CEO & MD Sahrsh Davuluri said the quarter saw a dip in performance, H1FY27 was largely in line with plan, and growth expectations remain intact for FY27 and the following year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Nov 2026 | board outcome Capex, Results | Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryNeuland Laboratories' board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 on November 3, 2026, with limited review reports from statutory auditors MSKA & Associates LLP. Consolidated revenue from operations for the quarter ended September 30, 2026 was Rs 44,965.69 lakhs, against Rs 64,157.71 lakhs in the June 30, 2026 quarter and Rs 51,427.31 lakhs in the September 30, 2025 quarter. Consolidated profit for the quarter ended September 30, 2026 was Rs 5,162.50 lakhs; basic and diluted EPS was Rs 40.24 (face value Rs 10). For the half year ended September 30, 2026, consolidated revenue from operations was Rs 1,09,123.40 lakhs and profit was Rs 19,929.81 lakhs. The board also approved capital expenditure of about Rs 47.1 crore (incl. GST) for acquiring a 6-acre land parcel at Domadugu Village, Sangareddy District, Telangana, funded through internal accruals, for future capacity expansion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 25 Aug 2026 | credit rating Rating | Neuland Laboratories Limited has informed the Exchange about Credit RatingAI summaryNeuland Laboratories intimated under Regulation 30 of SEBI Listing Regulations that Crisil Ratings has reaffirmed the Company's credit ratings. Long-term rating: CRISIL A+/Positive, reaffirmed with outlook revised to 'Positive'. Short-term rating: CRISIL A1, reaffirmed. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Aug 2026 | transcript Capex, Guidance, Results | Transcript of the Earnings Call conducted on August 5, 2026AI summaryNeuland Laboratories filed the transcript of its Q1 FY27 earnings call held on August 5, 2026 for the quarter ended June 30, 2026, and said it has been uploaded to its website. Management said total income was INR650.1 crores versus INR300.6 crores a year earlier (growth of 16.3%), EBITDA was INR231.1 crores (margin 35.5%), and profit after tax was INR147.4 crores versus INR13.7 crores in Q1 FY26. Management said working capital days improved from 137 days at end-FY26 to 84 days in FY27, and capex outflow in the quarter was INR121.6 crores, mainly for new R&D and peptide facilities. Management said it approved capital investments of about INR203 crores during the quarter and has spent INR870 crores against total approved capex of INR1,460 crores over the last 13 quarters. Management said it aspires to grow about 20% and expects FY27 and FY28 to grow that way, but declined to give a specific FY27 growth guidance, and said quarterly performance is inherently uneven. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | presentation Capex, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q1FY27 results (quarter ended June 30, 2026). Total income for Q1FY27 was Rs. 650.1 crore, up 116.3% YoY; EBITDA was Rs. 231.1 crore (EBITDA margin 35.5%); PAT was Rs. 147.4 crore. Net debt stood at Rs. (308.5) crore at Q1FY27 end, compared with Rs. (156.8) crore at Q4FY26 end. Working capital days of sale were 84 days in Q1FY27 against 137 days in Q4FY26; capex outflow was Rs. 122 crore in Q1FY27. CEO and MD Saharsh Davuluri said Q1 FY27 was broadly in line with expectations, that all significant capex projects are proceeding according to plan, and that the intensity of investments will further increase based on opportunities available. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2026 | board outcome Capex, Legal, Results | Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryNeuland Laboratories' board, at its meeting on August 5, 2026, approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with limited review reports from the statutory auditors enclosed (the filing does not state the results figures). The board approved execution of an irrevocable, unconditional and continuing corporate guarantee of Rs. 40 crores in favour of Gland Pharma Limited, linked to a Loan Licence Agreement under which Gland Pharma will set up dedicated manufacturing capacity and incur capex for certain products; the company says there is no immediate impact on its financials and the guarantee is a contingent liability. The board approved capacity enhancement at Unit 1 (Bonthapally, Sangareddy District, Telangana): existing capacity 376.5 KL at 91% utilization, proposed addition of 18 KL within 6-7 months, investment of Rs. 39.8 crores (incl. GST) funded through internal accruals. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Jul 2026 | credit rating Rating | Neuland Laboratories Limited has informed the Exchange about Credit RatingAI summaryNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated July 13, 2026. India Ratings and Research has affirmed the Company's credit rating. Bank loan facilities are rated IND A+/Positive/IND A1 with rating action "Affirmed". Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 May 2026 | transcript Capex, Guidance, Results | Transcript of the Earnings Call conducted on May 12, 2026AI summaryNeuland Laboratories filed the transcript of its Q4 & FY26 earnings conference call held on May 12, 2026, uploaded to its website. Management reported Q4FY26 total income of INR788.7 crores, up 134.9% from INR335.8 crores, with gross margin of 62.1%, EBITDA of INR319.4 crores (40.5% margin) and profit after tax of INR212.5 crores. For FY26, revenue was INR2053.1 crores (up 37.1%), EBITDA INR603.4 crores (29.4% margin) and profit after tax INR363.1 crores; free cash flow was negative INR49.4 crores and working capital days rose to 137 from 107. CFO Abhijit Majumdar said Q4 EBITDA margin should not be seen as indicative of future performance; CEO Saharsh Davuluri said the company has not given formal guidance but expects visible growth over the next 2 to 3 years, with ROCE expected to moderate during longer capital deployment cycles. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | board outcome Capex, Dividend / buy-back, Management change, Results | Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, payable after shareholder approval at the 42nd AGM. Board approved appointment of Dr. Mauricio Futran (DIN: 11699767) as Additional Director (Non-Executive Non-Independent) w.e.f. May 12, 2026, subject to shareholder approval at the AGM. Board approved the 42nd AGM on August 4, 2026, and fixed July 24, 2026 as the record date for final dividend. Board approved capacity enhancement at Unit 1, Bonthapally, adding 120.5 KL to existing 256 KL capacity (91% utilization), within 12 to 18 months, with investment of Rs. 143.4 crores (incl. GST) funded by internal accruals and borrowings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | board outcome Capex, Dividend / buy-back, Management change, Results | Appointment of Dr. Mauricio Futran (DIN: 11699767), as an Additional Director of the Company, categorized as Non-Executive Non-Independent DirectorAI summaryBoard approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10; record date July 24, 2026; 42nd AGM on August 4, 2026. Board appointed Dr. Mauricio Futran (DIN: 11699767) as Additional Director (Non-Executive Non-Independent) w.e.f. May 12, 2026, subject to shareholder approval at the AGM. Board approved capacity enhancement at Unit 1, Bonthapally, adding 120.5 KL to existing 256 KL capacity (91% utilization), with investment of Rs. 143.4 crores (incl. GST) over 12 to 18 months, financed through internal accruals and borrowings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | presentation Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q4FY26 and FY26 financial results (quarter and year ended March 31, 2026). Q4FY26 total income was Rs. 788.7 crore (134.9% YoY); EBITDA Rs. 319.4 crore (448.6% YoY) with EBITDA margin of 40.5%; PAT Rs. 212.5 crore (666.3% YoY). Net debt was Rs. (156.8) crore at Q4FY26 end, against Rs. (228.7) crore at Q4FY25 end. Working capital days of sale were 137 days in Q4FY26, against 145 days in Q3FY26; capex outflow was Rs. 397 crore in FY26. CEO & MD Saharsh Davuluri said the company ended FY26 on a strong note in line with expectations, with good business visibility in the short to medium term, and that peptide manufacturing and the new R&D Centre investments are proceeding according to plan. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | dividend Capex, Dividend / buy-back, Guidance, Management change, Results | Audited Financial Results and recommendation of final dividend for financial year 2025-26AI summaryBoard approved audited standalone and consolidated (Ind AS) financial results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, for FY 2025-26, payable after approval at the 42nd AGM. Record date for the final dividend is July 24, 2026; the 42nd AGM is to be held on August 4, 2026. Board appointed Dr. Mauricio Futran (DIN: 11699767) as Additional Director (Non-Executive, Non-Independent) w.e.f. May 12, 2026, subject to shareholder approval at the AGM. Board approved capacity enhancement at Unit 1 (Bonthapally): capacity addition of 120.5 KL over 12 to 18 months on existing 256 KL, with investment of Rs. 143.4 crores (incl. GST), funded by internal accruals and borrowings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 May 2026 | board outcome Capex, Dividend / buy-back, Management change, Results | Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend For Financial Year 2025-26AI summaryBoard approved audited standalone and consolidated Ind AS results for the year ended March 31, 2026, with unmodified auditor opinion from MS KA & Associates LLP. Board recommended a final dividend of Rs. 34 per equity share (340%) on face value Rs. 10, payable on or after five days from declaration at the 42nd AGM; record date July 24, 2026. Board approved convening the 42nd AGM on August 4, 2026. Board appointed Dr. Mauricio Futran (DIN: 11699767) as Additional Director (Non-Executive, Non-Independent) w.e.f. May 12, 2026, subject to shareholder approval at the AGM. Board approved capacity enhancement at Unit 1, Bonthapally, adding 120.5 KL to existing 256 KL capacity (91% utilization), within 12 to 18 months, at investment of Rs. 143.4 crores (incl. GST), financed through internal accruals and borrowings. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 13 Feb 2026 | transcript Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about TranscriptAI summaryNeuland Laboratories filed the transcript of its Q3FY26 and 9MFY26 earnings conference call held on February 9, 2026. Abhijit Majumdar (CFO) said Q3FY26 total income was INR447.8 crores, up 11.4% YoY from INR401.9 crores, with gross margin at 52.1% versus 53.2% in Q3FY25 and EBITDA of INR85 crores at a 19% margin, or INR95 crores (21%) excluding a INR10 crore labour codes impact. Majumdar said Q3 profit before tax was INR54.3 crores before extraordinary items, quarterly EPS was INR31.5, capex outflow for 9MFY26 was INR254 crores, and free cash flow was negative INR9.2 crores. Saharsh Davuluri (Vice-Chairman and MD) said the quarter was in line with expectations, attributed lower margins to product mix and non-recognition of a high-margin CMS product and a delayed Paliperidone shipment, and declined to give specific Q4 or FY26 guidance. Davuluri said the peptide capacity is slated for commissioning in July and that management hopes to secure at least one commercial peptide manufacturing arrangement in FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | presentation Capex, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q3FY26 and 9MFY26 results (quarter and nine months ended December 31, 2025). Q3FY26 total income was Rs. 447.8 crore, up 11.4% YoY; EBITDA was Rs. 85.0 crore (down 6% YoY) at a 19.0% margin (down 350 bps YoY); PAT was Rs. 40.4 crore (down 60% YoY). Net debt stood at Rs. (202.6) crore at end-Q3FY26 versus Rs. (6.6) crore at end-Q2FY26. Working capital days of sale were 145 in Q3FY26 against 155 in Q2FY26, mainly due to lower receivables; capex outflow was Rs. 254 crore in 9MFY26. Management said revenues were in line with the outlook for the year, but product mix and higher operating expenses reduced EBITDA margins; the Board approved moving R&D to a leased 140k sq ft facility at Genome Valley. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 09 Feb 2026 | board outcome Results | Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025AI summaryNeuland Laboratories filed the outcome of its board meeting held February 9, 2026, approving unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025. Consolidated revenue from operations for Q3 FY26 (quarter ended December 31, 2025) was Rs 43,970.93 lakhs, against Rs 51,427.31 lakhs in the previous quarter and Rs 39,803.18 lakhs in the year-ago quarter. Consolidated profit for the period for the quarter was Rs 4,057.19 lakhs, against Rs 9,685.39 lakhs in the previous quarter and Rs 10,158.68 lakhs in the year-ago quarter. Consolidated revenue from operations for the nine months ended December 31, 2025 was Rs 1,24,673.51 lakhs, against Rs 1,14,847.73 lakhs a year earlier; profit for the period was Rs 15,132.58 lakhs, against Rs 23,230.22 lakhs. Basic and diluted EPS for the quarter was Rs 31.62 (face value Rs 10). The statutory auditors issued a limited review report with an unmodified conclusion. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 12 Nov 2025 | transcript Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about TranscriptAI summaryNeuland Laboratories filed the transcript of its Q2 & H1 FY26 earnings conference call held on November 7, 2025, under Regulation 30 of the SEBI LODR Regulations. Management said Q2 FY26 total income was Rs. 516 crores odd, up 63.7% from Rs. 315 crores in the same period last year, with EBITDA of Rs. 156.9 crores at a 30.4% margin and profit after tax of Rs. 96.5 crores (EPS Rs. 75.18). Management said FY26 would be a year of strong growth on a base of FY24, not FY25, and declined to give quarter-specific guidance for Q3 and Q4. Management said working capital stood at 155 days of sales and net debt at negative Rs. 6.6 crores, with capex of Rs. 91 crores in the quarter and Rs. 170.7 crores for the six months. Management said the four-module peptide facility's Module-1 is expected to be operational by next financial year, and that the capacity in kilograms or tons could not be specified. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | presentation Capex, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryInvestor/analyst presentation on Q2FY26 and H1FY26 financial results (quarter and half year ended September 30, 2025), filed under Regulation 30. Q2FY26 total income Rs. 516.1 crore, up 63.7% YoY; EBITDA Rs. 156.9 crore, up 138.8% YoY; EBITDA margin 30.4%, up 960 bps YoY. Q2FY26 PAT Rs. 96.5 crore, up 201.6% YoY; net debt Rs. (-6.6) crore at Q2FY26 end (net cash position). Working capital days of sale were 155 in Q2FY26 versus 145 in Q1FY26, mainly due to higher receivables; capex outflow was Rs. 170 crore in H1FY26. Management (Suchdeth Davuluri) said record high revenue was driven by CMS commercial projects and that momentum is expected to continue through the rest of the year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 07 Nov 2025 | board outcome Results | Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025AI summaryNeuland Laboratories filed the outcome of its board meeting held November 7, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025. Consolidated revenue from operations for the quarter ended September 30, 2025 was Rs 51,427.31 lakhs, against Rs 29,275.27 lakhs in the previous quarter (June 30, 2025) and Rs 31,084.38 lakhs in the year-ago quarter. Consolidated net profit (profit for the period) for the quarter was Rs 9,685.39 lakhs, against Rs 1,390.00 lakhs in the previous quarter and Rs 3,284.27 lakhs in the year-ago quarter. Consolidated basic and diluted EPS for the quarter was Rs 75.49 (face value Rs 10), and for the half year ended September 30, 2025 was Rs 86.32. The statutory auditors, MS KA & Associates, issued a review report with an unmodified conclusion on the consolidated results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Aug 2025 | transcript Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about TranscriptAI summaryNeuland Laboratories filed the transcript of its Q1FY26 earnings conference call held on July 31, 2025 for the quarter ended June 30, 2025. Management reported total income of Rs. 300.6 crores, down 32.4% year-on-year from Rs. 444 crores, with EBITDA of Rs. 42.1 crores (14.4% margin) and profit after tax of Rs. 13.7 crores versus Rs. 98.3 crores in Q1FY25. CFO Abhijit Majumdar said free cash flow was negative Rs. 66 crores, working capital was 145 days of sales, net debt was a negative Rs. 165 crores (net cash), and capex outflow was Rs. 79 crores. Management said the quarter was below par due to customer order flow, but reiterated its expectation that FY26 growth will resume on the FY24 base, with Unit 3 production block commercialisation expected to give revenue momentum from the second half of FY26. Management also said a further CMS molecule is expected to be commercialised in FY26 and that the peptide facility is expected to be completed in the next financial year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2025 | presentation Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q1FY26 (quarter ended June 30, 2025) results under Regulation 30. Q1FY26 total income was Rs. 300.6 crore (down 32.4% YoY); EBITDA was Rs. 42.1 crore (down 67.2% YoY), with EBITDA margin at 14%; PAT was Rs. 13.7 crore (down 86.1% YoY, Q1FY25 included an exceptional item). Net debt stood at Rs. (164.7) crore at Q1FY26 end, against Rs. (228.7) crore at Q4FY25 end. Management (Sucheth Davuluri) said Q1FY26 was below par due to the flow of customer orders but did not change its outlook on healthy growth expected this financial year. Management (Saharsh Davuluri) said it sees substantial growth this year from commercial molecules and continues to invest in people and capabilities. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 31 Jul 2025 | board outcome Management change, Results | Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryNeuland Laboratories reported standalone unaudited results for the quarter ended June 30, 2025: revenue from operations of Rs 29,275.27 lakhs, total income of Rs 30,060.86 lakhs, and profit after tax of Rs 1,370.76 lakhs (compared with Rs 9,835.29 lakhs for the quarter ended June 30, 2024 on a total income of Rs 33,582.38 lakhs). Consolidated unaudited results for the same quarter were also approved; the filing includes limited review reports from the statutory auditors on both standalone and consolidated results. The Board, at its meeting on July 31, 2025, approved the appointment of Dr. Ravi Shankar Gopinath (DIN: 00803847) as an Additional Director, categorised as Independent, for a term of five consecutive years effective August 1, 2025, subject to shareholder approval. The Board meeting ran from 1:30 p.m. to 3:47 p.m. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Jun 2025 | credit rating Rating | Neuland Laboratories Limited has informed the Exchange about Credit RatingAI summaryNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated June 21, 2025. CRISIL Ratings has reaffirmed the company's long-term rating at CRISIL A+/Stable. CRISIL Ratings has also reaffirmed the company's short-term rating at CRISIL A1. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 19 May 2025 | transcript Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about TranscriptAI summaryNeuland Laboratories filed the transcript of its Q4 and FY25 earnings call held on May 15, 2025. Management (Abhijit Majumdar, CFO) reported Q4 FY25 total income of INR335.8 crores, down 14% year-on-year from INR390.4 crores, EBITDA of INR58.2 crores (17.3% margin) and profit after tax of INR27.7 crores versus INR67.6 crores in Q4 FY24. For FY25, total income was INR1,497.3 crores, a 4.7% decline from INR1,571.1 crores, and free cash flow was INR111 crores. Management said FY25 was a year of consolidation, that Unit 3 production block has been capitalized with commercial production expected in FY26, and that it expects growth to resume in FY26 on the FY24 base; it does not give quantitative guidance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | presentation Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its Q4FY25 and FY25 investor/analyst presentation under Regulation 30 of the SEBI LODR Regulations, dated May 15, 2025. Q4FY25 total income was Rs. 335.8 crore (down 14.0% YoY); EBITDA was Rs. 58.2 crore (down 48.1% YoY) with EBITDA margin at 17.3% (down 1140 bps YoY); PAT was Rs. 27.7 crore (down 59.0% YoY). FY25 Free Cash Flow generation was Rs. 111 crore and capex investment was Rs. 206.4 crore (vs Rs. 143.7 crore in FY24). Net debt stood at Rs. (228.7) crore at Q4FY25 end. Management said FY25 revenue marginally declined versus FY24, in line with its initial outlook, and that it expects growth to resume in FY26 as molecules at take-off stage contribute; the peptide investment plan is on track. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | dividend Dividend / buy-back, Legal, Management change, Results | Neuland Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 15, 2025, recommended Final Dividend of Rs. 12 per equity share.AI summaryBoard of Neuland Laboratories approved audited standalone and consolidated Ind AS results for the year ended March 31, 2025, with unmodified auditor opinion from MSKA & Associates. Board recommended a final dividend of Rs. 12 per equity share (120%) on face value Rs. 10 for FY 2024-25, payable on or after five days from declaration at the 41st AGM. Record date for final dividend fixed as July 18, 2025; 41st AGM convened for July 30, 2025. Board approved re-appointment of Mr. Davuluri Saharsh Rao as Whole Time Director, designated Vice Chairman & Managing Director, for five years w.e.f. June 1, 2025, subject to shareholder approval at the AGM. Board approved appointment of M/s P.S. Rao & Associates as Secretarial Auditors for five consecutive financial years from April 1, 2025 to March 31, 2030, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 15 May 2025 | board outcome Dividend / buy-back, Legal, Management change, Results | Neuland Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on May 15, 2025.AI summaryNeuland Laboratories' board approved audited standalone and consolidated Ind AS financial results for the year ended March 31, 2025, with unmodified auditor opinion from MSKA & Associates. Board recommended a final dividend of Rs. 12 per equity share (120%) on face value Rs. 10 for FY 2024-25, payable after shareholder approval at the 41st AGM. Board approved re-appointment of Mr. Davuluri Saharsh Rao as Whole Time Director, designated Vice Chairman & Managing Director, for five years from June 1, 2025, subject to shareholder approval. 41st AGM set for July 30, 2025; dividend record date fixed as July 18, 2025. Board approved appointment of M/s P.S. Rao & Associates as Secretarial Auditors for five financial years from April 1, 2025 to March 31, 2030, subject to shareholder approval. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Mar 2025 | credit rating Rating | Neuland Laboratories Limited has informed the Exchange about Credit RatingAI summaryNeuland Laboratories Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations dated March 10, 2025. India Ratings and Research has affirmed the Company's long-term rating at IND A+/Positive. Fund-based limits are affirmed at IND A+/Positive / IND A1, and non-fund-based limits at IND A1. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 14 Feb 2025 | transcript Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about TranscriptAI summaryNeuland Laboratories filed the transcript of its Q3 and 9MFY25 earnings call held on February 11, 2025, under Regulation 30 of the SEBI LODR Regulations. Management said Q3 total income was Rs. 401.9 crores, up 1.8% year-on-year, and Q3 EBITDA excluding exceptional items was Rs. 90.3 crores (margin 22.5%) versus Rs. 122.7 crores in Q3FY24. For 9MFY25, revenue was Rs. 1,161.5 crores against Rs. 1,180.8 crores, and EBITDA excluding exceptional items was Rs. 284.6 crores against Rs. 362 crores; management expects FY25 to be flat. Management said it invested Rs. 147 crores in capex in the nine months and is building a peptide facility (Rs. 254 crores approved investment, per the analyst's figure), with commercial production at Unit III expected in FY26. Management declined to comment on specific CMS molecules, citing confidentiality. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2025 | results Results | Integrated filing (Financial) for quarter and nine months ended December 31, 2024AI summaryNeuland Laboratories filed its integrated financial filing for the quarter and nine months ended December 31, 2024, with the auditor's limited review report (MSKA & Associates) on consolidated unaudited results. Q3 FY25 consolidated revenue from operations was Rs. 39,803.18 lakhs, against Rs. 31,084.38 lakhs in the previous quarter and Rs. 39,282.83 lakhs in the year-ago quarter. Q3 FY25 consolidated profit for the period was Rs. 10,158.68 lakhs, including an exceptional gain of Rs. 5,577.80 lakhs from the perpetual lease transfer of an investment property in Nanakramguda, Hyderabad. Nine-month consolidated revenue from operations was Rs. 114,847.73 lakhs (Rs. 117,357.08 lakhs a year earlier), and nine-month profit for the period was Rs. 23,230.22 lakhs (Rs. 23,251.70 lakhs). Quarterly basic EPS was Rs. 79.18 (not annualised). Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2025 | presentation Capex, Guidance, Results | Neuland Laboratories Limited has informed the Exchange about Investor PresentationAI summaryNeuland Laboratories filed its investor/analyst presentation on Q3FY25 and 9MFY25 results (quarter and nine months ended December 31, 2024). Q3FY25 total income was Rs. 401.9 crore (+1.8% YoY); EBITDA was Rs. 90.3 crore (down 26.4% YoY) with EBITDA margin at 22.5% (down 860 bps YoY). Q3FY25 PAT was Rs. 101.4 crore (+25.6% YoY), including an exceptional profit on investment property of Rs. 55.8 crore. Net debt stood at Rs. (185.1) crore at Q3FY25 end, with 9MFY25 free cash flow of Rs. 70.8 crore and capex of Rs. 147 crore. Management said the quarter's results align with its initial FY25 outlook, that it is confident on business momentum for the medium and long term, and that it has decided to invest in larger peptides capacity. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 10 Feb 2025 | results Results | Neuland Laboratories Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryNeuland Laboratories filed unaudited consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on February 10, 2025. Q3 FY25 consolidated revenue from operations was Rs 39,803.18 lakhs, against Rs 31,084.38 lakhs in the quarter ended September 30, 2024 and Rs 39,282.83 lakhs in the quarter ended December 31, 2023. Q3 FY25 consolidated profit for the period was Rs 10,158.68 lakhs, including an exceptional item of Rs 5,577.80 lakhs from the transfer of an investment property at Nanakramguda, Hyderabad, through perpetual lease. Nine-month consolidated revenue from operations was Rs 114,847.73 lakhs (Rs 117,357.08 lakhs in the prior-year nine months), and nine-month profit for the period was Rs 23,230.22 lakhs. Quarterly basic EPS was Rs 79.18 (not annualised), against Rs 25.60 in the previous quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.